ArticleAsia Pacific allergy2023
Thyroid disease post-COVID-19 infection: Report of a case with new-onset autoimmune thyroid disease.
Article in Asia Pacific allergy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Autoimmune Thyroid Diseases After COVID-19 Infection: A Systematic Review of Clinical Manifestation and Outcomes.International journal of environmental research and public health · 2026Pooled it
- Long-Term Thyroid Complications Post-COVID-19: A Systematic Review.Microorganisms · 2026Review
- New-onset autoimmune thyroid disease following COVID-19.Asia Pacific allergy · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present hyperthyroidism with autoimmune thyroid disease, which developed a few weeks after the COVID-19 infection in a patient with no prior thyroid disease. Our case was described with clinical presentations, diagnostic tests, and subsequent patient management and compared to other similar reported cases. A 28-year-old female patient with no prior history of thyroid dysfunction developed hyperthyroidism 8 weeks after COVID-19 infection, confirmed by low thyroid stimulating hormone, high free thyroxine 4, and thyroid receptor antibody. She was treated and responded well to methimazole 20 mg in a few weeks. We searched the literature and found three other similar reported cases and compared those. The effects of COVID-19 infection on the immune system and the thyroid gland might explain the pathology of hyperthyroidism post-COVID-19 infection in this patient. This new-onset hyperthyroidism was found in a woman with mild symptoms and responded well to thiamazole and β-blockers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.